Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma

Celia Lara-Morga; Magda Palka-Kotlowska; Sara Custodio-Cabello; Vilma Pacheco-Barcia; Luis Cabezón-Gutiérrez

doi:10.37349/etat.2023.00136

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma

Explor Target Antitumor Ther. 2023;4(2):307-315. doi: 10.37349/etat.2023.00136. Epub 2023 Apr 27.

Authors

Celia Lara-Morga¹, Magda Palka-Kotlowska^{1

2}, Sara Custodio-Cabello^{1

2}, Vilma Pacheco-Barcia^{1

2}, Luis Cabezón-Gutiérrez^{1

2}

Affiliations

¹ Facultad de Medicina, Universidad Francisco Vitoria, 28223 Pozuelo de Alarcón, Madrid, Spain.
² Medical Oncology, Hospital Universitario de Torrejón, 28850 Torrejón de Ardoz, Madrid, Spain.

Abstract

A clinical case of a 61-year-old female diagnosed with stage IV right colon adenocarcinoma (unresectable liver and multiple lymph node metastases at the time of diagnosis), Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma rat sarcoma viral oncogene homolog (NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type, proficient mismatch repair (pMMR), in whom a complete response to the third-line of systemic treatment with trifluridine/tipiracil (TAS-102) was obtained. The complete response has been maintained for more than 2 years after its suspension.

Keywords: Complete response; colorectal cancer; trifluridine/tipiracil (TAS-102).

Publication types

Case Reports